Oxford Science Enterprises

📢 #PortfolioNews Congratulations to Theolytics on the appointment of David Apelian MD, PhD, MBA as their new CEO. David is an experienced CEO and leader in the biotech industry who has worked across all phases of drug development. He joins at an important time for Theolytics, as they advance their first clinical trial in ovarian cancer. We look forward to supporting David and the Theolytics team as they continue their work to develop the next-generation of immunotherapies for the treatment of cancer. You can find out more about David here: https://lnkd.in/ePybPa6D #Biotech #Innovation

🔦 Here’s the latest round-up from across our portfolio: 📢 Beacon Therapeutics marks major trial progress Beacon Therapeutics has announced promising 3-month results from the company’s phase 2 DAWN trial of laru-zoVA (AGTC-501) for patients with X-linked retinitis pigmentosa (XLRP). This marks a significant step forward in advancing treatments for inherited retinal diseases. 🎉 New Leadership at OMass Therapeutics OMass Therapeutics has strengthened its leadership team with two key promotions. Hsin Loke has been promoted to Chief Operating Officer and Jon Roffey has been promoted to Senior Vice President, Discovery and Non-Clinical. ⭐️ PQShield announces boardroom expansion PQShield appointed Antonio J. Viana to its board of directors, alongside adding Mike Muller, RoseMary Schooler and Ian Drew to its strategic advisory board, preparing the company for global commercial growth in 2025 and beyond. 🚀 Sam Harman promoted to Partner & Head of Deep Tech at OSE We’re thrilled to announce that Sam Harman has been promoted to Partner and Head of Deep Tech. Sam has been instrumental in shaping OSE’s Deep Tech strategy, helping academic founders build groundbreaking companies across our portfolio in areas including quantum computing, AI, and robotics. #Innovation #Oxford

📢 We’re thrilled to announce that Sam Harman has been promoted to Partner and will now lead our Deep Tech practice full-time! Sam has been a pivotal figure at OSE, helping uncover and back groundbreaking companies across quantum computing, AI, and robotics. As Head of Deep Tech, Sam will continue to focus on identifying and nurturing transformative science and technology from across the Oxford innovation ecosystem in addition to supporting the growth of our current portfolio and team. #DeepTech #Leadership #Innovation

🎬 Earlier this year we partnered with Cambridge Innovation Capital and Northern Gritstone, to co-host the first university spinout showcase, welcoming over 300 institutional investors, including Mansion House signatories, pension funds, global venture investors, asset managers, and UK policymakers. It was an amazing day, full of energy, as we shared the latest innovations from UK university spinouts, and looked at the potential they have to change the world. A big thank you again to everyone involved for making it a success! Here’s to driving the future of UK innovation together⚡

🔦 Here’s the latest round-up of exciting news from across our portfolio: 💽 Oxford Ionics Partners with Airbus Oxford Ionics, Quanscient, and Airbus have teamed up to revolutionise computational fluid dynamics using quantum computing. This partnership, part of the UK’s SparQ programme, looks to transform aerospace design through enhanced simulation accuracy and efficiency. 🏆 Caristo Diagnostics Wins Big Caristo Diagnostics has been named a winner of the Fierce Healthcare Innovation Awards 2024 for its cutting-edge AI technology used in cardiovascular risk prediction. 🫁 Albus Health Asthma Breakthrough Results from a clinical study at the British Thoracic Society Winter Meeting 2024 this week showed Albus Health’s AI-powered Albus Home device can detect asthma attack warning signs up to five days in advance. This technology is set to transform respiratory care and clinical trials. 💊 AlveoGene Earns FDA Recognition AlveoGene’s inhaled gene therapy, AVG-002, has been granted Orphan Drug Designation by the FDA for its potential to address SP-B deficiency in newborns. The designation is for those looking to treat, prevent, or diagnose rare diseases. 📈 Oxford Flow Secures $25M Oxford Flow raised $25M in a Series C round co-led by bp Ventures and Energy Impact Partners. The funding will scale production and expand their team to address critical energy challenges. #innovation

🚀 Congratulations to Oxford Flow on their $25M Series C fundraise! We are proud to continue supporting the Oxford Flow team as they scale their operations and deliver cutting-edge valve technology that’s transforming the energy sector. This latest investment, co-led by bp Ventures and Energy Impact Partners will enable Oxford Flow to expand production, grow their team, and address critical challenges in the energy sector, including reducing fugitive emissions and lowering maintenance costs. #Innovation #deeptech #oxford

🔦 Here’s the latest weekly round-up of exciting news from across our portfolio: 🌍 Genomics Tackling Global Obesity Genomics’ cutting-edge work in digital healthcare to combat obesity was recently featured in The Times. By integrating genomic insights with digital health tools, they are helping pave the way for more personalised and effective treatments to fight obesity. 🧪 Refeyn Launches StreamlineMP Software Platform Refeyn has unveiled a new software platform designed to accelerate key bioanalytical workflows. This will enhance both productivity and accuracy in the life sciences sector, to better support critical research and development. 🧬 Nucleome Therapeutics Presents Research at Dark Genome Symposium in New York Principal Scientist, Chantal Hargreaves, presented Nucleome's research on their high resolution genetic mapping approach which has identified a novel disease target for rheumatoid arthritis. 🖥️ Oxford Ionics Featured in Forbes CEO of Oxford Ionics Chris Ballance spoke to Forbes about the state of Quantum computing today.

❗Reminder - Applications are open for the Oxford Venture Scouts Programme Apply now to shape the next wave of innovation! 👉 https://lnkd.in/gcHAtvFD Oxford Venture Scouts is seeking visionary founders to transform groundbreaking science and technology into market-leading ventures. Whether you’re driving innovation in health tech, deep tech, or life sciences, or an industry expert looking to launch a new opportunity, we want to hear from you. Supported by OSE, Oxford University Innovation, the University of Oxford, and Parkwalk Advisors, this programme offers: ✅ Access to world-class scientific teams ✅ Comprehensive venture-building support ✅ Up to £0.25M investment to spin out your company 📅 Deadline: 31 Dec 2024 #OxfordVentureScouts #DeepTech #HealthTech #LifeSciences #Innovation #Entrepreneurship

🔦 Here’s this week’s round-up of exciting news from across our portfolio: 🎥 Oxford Ionics on CNBC Chris Ballance, Co-Founder & CEO of Oxford Ionics, spoke to CNBC about the transformative potential of quantum computing. 🌟CEO of OMass Therapeutics wins major award Congratulations to Ros Deegan, CEO of OMass Therapeutics for winning this year’s Women-Led Business Leader of the Year, at the Life Star Awards! A well-deserved recognition for Ros’ incredible leadership. 💉 Theolytics Begins First-In-Human Trial Theolytics has dosed the first patient in their Phase I/IIa trial of THEO-260, a novel oncolytic immunotherapy for advanced-stage platinum-resistant ovarian cancer. This milestone marks a major step forward in tackling the challenging disease. 🏆 Neu Health bestowed NHS Journal Award Congratulations to the Neu Health team for winning the NHS Journal Award for digitising patient care. Awarded at an event with over 2,000 people, opened by the Secretary for State for Health, Wes Streeting, the awards honour exceptional achievements in the NHS. 🏢 Oxford University Innovation in Forbes “Each company formed represents major progress,” says Dr Mairi Gibbs, CEO of OUI, featured in a recent Forbes piece speaking about how spinout creation has continued to accelerate despite current state of capital markets. 🩺 FDA Recognition for Ultromics Ultromics achieved FDA Breakthrough Device Clearance for its cardiac amyloidosis screening device, enhancing early detection capabilities for a condition often diagnosed too late.

📽️ #MeetThePortfolio - Refeyn 🔬 Led by CEO Gerry Mackay, Refeyn is redefining the molecular research landscape through mass photometry—a revolutionary technique for better measuring molecular mass, by simply shining light on single biomolecules. Refeyn's technology emerged from a breakthrough moment in 2014 when researchers from the University of Oxford discovered that a light microscope could measure individual proteins' mass. By 2018, the team had transformed this concept into a quantitative tool. Today, valued at over $250 million and with a global team of 150+, Refeyn’s instruments are empowering scientists worldwide, from pharmaceutical labs to academic research. #innovation #healthtech #lifesciences #oxford